Latest Pharma and Biotech News
Pharmaceutical
23 June 2025 Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic.
Today's issue
Refine Search
Generics
The revision of the European pharmaceutical legislation, the reform of the Supplementary Protection Certificate (SPC) system and the review of the SPC manufacturing waiver are now fundamental reforms to stimulate a strong off-patent pharmaceutical industry in Europe whose medicines account for the vast majority of those dispensed in Europe, trade group Medicines for Europe announced today. 24 June 2025
Biotechnology
Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its progression into Phase III clinical development. 24 June 2025
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk yesterday announced that it will no longer be working with Hims & Hers Health on direct access to its blockbuster obesity drug Wegovy (semaglutide) that will no longer be available to Hims & Hers Health via NovoCare Pharmacy. 24 June 2025
Biotechnology
AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate the development of next-generation immunotherapies using Plectonic’s LOGIBODY platform. 24 June 2025
Pharmaceutical
Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. 24 June 2025
Biotechnology
Licensing of innovator oligonucleotide drugs for central nervous system (CNS) indications surged 339% in 2024, jumping from $640 million to $2.81 billion, according to research from GlobalData. 24 June 2025
Biotechnology
New Jersey, USA-based clinical-stage biotech OnCusp Therapeutics has announced the appointment of Dr Dimitry Nuyten as chief medical officer (CMO). 24 June 2025
Pharmaceutical
Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than double after announcing positive Phase IIb NAVIGATE results for its once‑per‑season influenza prevention therapy, CD388. 24 June 2025
Biotechnology
European biotech argenx has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic inflammatory demyelinating polyneuropathy (CIDP), marking the first regulatory green light for a novel mechanism in this condition in over three decades. 23 June 2025
Pharmaceutical
US pharma major Eli Lilly spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy orforglipron at the American Diabetes Association meeting, revealing no liver toxicity and further bolstering its position in the growing diabetes and obesity treatment market. 23 June 2025
Biotechnology
Psychedelic medicines company Compass Pathways was trading 46% lower midday Monday. 23 June 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma today announced the appointment of Andrew Smith as chief operating officer (COO). 23 June 2025
Biotechnology
The Alliance for Regeneration Medicine (ARM), a trade group that represents more than 400 members companies across 25 countries, including emerging and established biotech firms, has taken aim at the powers that be in US healthcare. 23 June 2025
Biotechnology
Japan’s Otsuka has entered into an exclusive, worldwide licensing agreement with China and USA-based Harbour BioMed for the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager under development by Harbour BioMed. 23 June 2025
Pharmaceutical
US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. 23 June 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. 23 June 2025
Biotechnology
Danish CNS specialist Lundbeck announced the full results from the Phase IV RESOLUTION trial at the 11th Congress of the European Academy of Neurology taking place in Helsinki, Finland. 23 June 2025
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has pointed to the role that it has played over more than a decade in increasing transparency in pharma’s payments to healthcare professionals (HCPs), healthcare organizations (HCOs) and patient organisations (POs). 23 June 2025
Pharmaceutical
Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. 23 June 2025
Pharmaceutical
US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase I/II portion of the Phase I/II/III FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). 23 June 2025
All news
Generics
The revision of the European pharmaceutical legislation, the reform of the Supplementary Protection Certificate (SPC) system and the review of the SPC manufacturing waiver are now fundamental reforms to stimulate a strong off-patent pharmaceutical industry in Europe whose medicines account for the vast majority of those dispensed in Europe, trade group Medicines for Europe announced today. 24 June 2025
Biotechnology
Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its progression into Phase III clinical development. 24 June 2025
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk yesterday announced that it will no longer be working with Hims & Hers Health on direct access to its blockbuster obesity drug Wegovy (semaglutide) that will no longer be available to Hims & Hers Health via NovoCare Pharmacy. 24 June 2025
Biotechnology
AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate the development of next-generation immunotherapies using Plectonic’s LOGIBODY platform. 24 June 2025
Pharmaceutical
Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. 24 June 2025
Biotechnology
Licensing of innovator oligonucleotide drugs for central nervous system (CNS) indications surged 339% in 2024, jumping from $640 million to $2.81 billion, according to research from GlobalData. 24 June 2025
Biotechnology
New Jersey, USA-based clinical-stage biotech OnCusp Therapeutics has announced the appointment of Dr Dimitry Nuyten as chief medical officer (CMO). 24 June 2025
Pharmaceutical
Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than double after announcing positive Phase IIb NAVIGATE results for its once‑per‑season influenza prevention therapy, CD388. 24 June 2025
Biotechnology
European biotech argenx has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic inflammatory demyelinating polyneuropathy (CIDP), marking the first regulatory green light for a novel mechanism in this condition in over three decades. 23 June 2025
Pharmaceutical
US pharma major Eli Lilly spotlighted new safety and efficacy data for its investigational oral GLP-1 therapy orforglipron at the American Diabetes Association meeting, revealing no liver toxicity and further bolstering its position in the growing diabetes and obesity treatment market. 23 June 2025
Biotechnology
Psychedelic medicines company Compass Pathways was trading 46% lower midday Monday. 23 June 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma today announced the appointment of Andrew Smith as chief operating officer (COO). 23 June 2025
Biotechnology
The Alliance for Regeneration Medicine (ARM), a trade group that represents more than 400 members companies across 25 countries, including emerging and established biotech firms, has taken aim at the powers that be in US healthcare. 23 June 2025
Biotechnology
Japan’s Otsuka has entered into an exclusive, worldwide licensing agreement with China and USA-based Harbour BioMed for the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager under development by Harbour BioMed. 23 June 2025
Pharmaceutical
US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. 23 June 2025
Pharmaceutical
US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. 23 June 2025
Biotechnology
Danish CNS specialist Lundbeck announced the full results from the Phase IV RESOLUTION trial at the 11th Congress of the European Academy of Neurology taking place in Helsinki, Finland. 23 June 2025
Pharmaceutical
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has pointed to the role that it has played over more than a decade in increasing transparency in pharma’s payments to healthcare professionals (HCPs), healthcare organizations (HCOs) and patient organisations (POs). 23 June 2025
Pharmaceutical
Swiss drugmaker Idorsia today announced that Simcere Pharmaceuticals (HK: 2096) has received approval for Quviviq (daridorexant) from the Chinese National Medical Products Administration for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, with no psychotropic drug control labeling. 23 June 2025
Pharmaceutical
US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase I/II portion of the Phase I/II/III FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). 23 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze